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Simple Summary: Cervical cancer (CC) is managed mainly using subjective and conventional
methods. Research about the molecular mechanisms of micro-RNA-877-3p (miR-877-3p) in other
cancer types revealed that it interacts with events that are important for CC. Our aim was to
understand the role of miR-877-3p in CC. We observed that it was overexpressed in cervical tumors
compared with benign lesions, and that it promoted CC cell migration and invasion by modulating
cytoskeletal protein folding, which potentiated the effects caused by paclitaxel, one of the most
common therapeutic drugs used in CC. We demonstrated a functional link between miR-877-3p and
one of its predicted targets, ZNF177. The expression and subcellular location of ZNF177 objectively
distinguished two CC entities and predicted poor outcome in the most aggressive form. Therefore,
the understanding of the molecular mechanisms driven by miR-877-3p provides useful tools for CC
clinical management, currently lacking of molecular biomarkers and targeted therapies.
Abstract: No therapeutic targets and molecular biomarkers are available in cervical cancer (CC)
management. In other cancer types, micro-RNA-877-3p (miR-877-3p) has been associated with
events relevant for CC development. Thus, we aimed to determine miR-877-3p role in CC. miR-
877-3p levels were examined by quantitative-PCR in 117 cervical lesions and tumors. Effects on
CC cell proliferation, migration, and invasion were evaluated upon anti-miR-877-3p transfection.
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miR-877-3p dependent molecular mechanism was comprehensively explored by proteomics, dual-
luciferase reporter assay, western blot, and immunohistochemistry. Cervical tumors expressed
higher miR-877-3p levels than benign lesions. miR-877-3p promoted CC cell migration and invasion,
at least partly by modulating cytoskeletal protein folding through the chaperonin-containing T-
complex protein 1 complex. Notably, miR-877-3p silencing synergized with paclitaxel. Interestingly,
miR-877-3p downregulated the levels of an in silico-predicted target, ZNF177, whose expression
and subcellular location significantly distinguished high-grade squamous intraepithelial lesions
(HSILs) and squamous cell carcinomas of the cervix (SCCCs). Cytoplasmic ZNF177 was significantly
associated with worse progression-free survival in SCCC. Our results suggest that: (i) miR-877-3p
is a potential therapeutic target whose inhibition improves paclitaxel effects; (ii) the expression
and location of its target ZNF177 could be diagnostic biomarkers between HSIL and SCCC; and
(iii) cytoplasmic ZNF177 is a poor-prognosis biomarker in SCCC.
Keywords: miR-877-3p; ZNF177; therapeutic target; predictive biomarker; CCT3; TCP-1; cytoskeletal
protein folding; squamous cell carcinoma of the cervix; high-grade squamous intraepithelial lesion;
cervical cancer
1. Introduction
According to the World Health Organization, cervical cancer (CC) is the fourth most
frequent tumor type among women worldwide, and has a five-year survival of 57–67%
in Europe [1,2]. This dismal outcome is partially due to it tending to be diagnosed at ad-
vanced stages, when treatments are less likely to succeed, because early phases are usually
asymptomatic [2]. Additionally, at present, CC clinical management has several limitations
that affect its poor prognosis: diagnosis is mainly based on the subjective interpretation
of tissue morphology, there are no molecular biomarkers that can predict prognosis, and
current therapies are not targeted, but based on conventional chemotherapy, radiother-
apy, and surgery [2–5]. According to the European Society of Medical Oncology Clinical
Practice Guidelines [2], while surgery is indicated for patients with local/locoregional
disease, chemoradiotherapy involving paclitaxel and cisplatin combined with bevacizumab
is considered the preferred first-line regimen in metastatic or recurrent CC, with a highest
median overall survival of only 16.8 months.
These drawbacks are particularly serious in the management of two stages of CC
development: high-grade squamous intraepithelial lesion (HSIL) and squamous cell car-
cinoma of the cervix (SCCC). A high-risk human papillomavirus (HR-HPV) infection in
the cervical epithelium can lead to a benign lesion (BL). If the infection persists in dividing
cells, the lesion can evolve towards an HSIL. At this stage, if some molecular alterations
arise concomitantly, the tumor may invade the basement membrane of the epithelium and
become an SCCC [3,6]. As tumor development is a continuous process, it is not surprising
that an HSIL that has already started to invade morphologically resembles an SCCC that
has just penetrated the basement membrane. HSIL patients are treated by surgery, which is
successful in more than 85% of cases [7], while SCCC patients receive a more aggressive
treatment that, unfortunately, is ineffective in around 50% of patients, who eventually
die from the disease [2]. Since diagnosis of these entities mainly relies on the subjective
evaluation of tissue morphology, some reports have evidenced the need of objectively
measurable strategies to distinguish HSIL and SCCC [8,9]. New diagnostic, prognostic,
and therapeutic approaches are therefore needed if the current weaknesses of CC clinical
management are to be overcome and the life expectancy of these patients improved.
Molecular biomarkers have proved to be very useful in many cancer types, as they
are objective, quantitative, and easy to reproduce and standardize among laboratories
and hospitals [10–14]. They have significantly improved prediction of diagnosis, prog-
nosis, and therapeutic response in breast [10], lung [15], and colorectal [16] cancers, and
glioblastoma [17]. Thus, the use of molecular biomarkers supported by the understanding
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of CC molecular pathogenesis would enable a more accurate clinical handling of these
patients [18]. In fact, the European Society of Medical Oncology has strongly recommended
more research to identify molecular biomarkers in CC [2].
The pathogenic mechanisms of CC are not fully understood at present. Although it
is widely recognized that persistent HR-HPV infection is the main cause of CC, since it
is present in 99.7% of cases, additional molecular changes are necessary to immortalize
and transform cervical epithelial cells [6,19]. Epigenetic alterations have been highlighted
among these changes, because they could be useful tools for cancer screening, early de-
tection, prognosis prediction, and therapy, given their reversible nature. While DNA
methylation and histone modification have been widely studied in CC [6,18,20,21], the
mechanisms and the role of micro-RNA (miRNA) deregulation in cervical carcinogenesis
are still to be determined [19]. miRNAs are short non-coding RNAs that modulate gene
expression by pairing with complementary nucleotide sequences, mainly of the 3′ untrans-
lated region (3′UTR) of the target mRNA, leading predominantly to mRNA cleavage or
protein translation repression [19,22,23]. Growing evidence reveals a profound deregu-
lation of miRNA expression in cancer [23,24], including CC [19,22,25–28]. However, a
very small overlap among those reports has been observed, probably due to the small
sizes of the series analyzed, potential sample selection biases due to poor suitability of
available material, and/or differences in study designs, populations, techniques, and data
analyses [19,29–31]. All these issues have limited our wider understanding of the specific
role of miRNAs in SCCC pathogenesis [19].
hsa-miR-877 is a human miRNA whose potential involvement in cancer has been
reported in several tumor types [32–35]. In particular, the contribution of the mature
miR-877-5p strand to cancer has been shown in non-small cell lung cancer [36] and glioblas-
toma [37], but mainly in tumors of the digestive tract, such as colorectal cancer [38,39],
pancreatic ductal adenocarcinoma [40], hepatocellular carcinoma [41], and distal bile duct
tumors [42]. Conversely, the involvement of the mature miR-877-3p strand in cancer has
been demonstrated in tumors, such as glioma [43], and bladder [44], and gastric cancer [45].
Despite these studies, very few articles have so far shed any light on the miR-877 molec-
ular mechanism in cancer, describing that miR-877 inhibited Toll-like receptor 4 (TLR4)
expression in glioma [43], activated p16 expression in bladder cancer [44], and restored
paclitaxel sensitivity in hepatocellular carcinoma [32]. Since TLR4 seems to be associated
with inflammation response against HPV and initiation and progression of CC [46–49], p16
overexpression is a hallmark of cervical malignancies [3,4], and paclitaxel is a conventional
chemotherapeutic agent for SCCC patients [2], we hypothesized that the miR-877-3p could
play an important role in CC. Therefore, we aimed to explore the molecular and clinical
involvement of miR-877-3p in cervical tumors.
2. Results
2.1. miR-877-3p is Overexpressed in Cervical Malignancies
To explore the potential involvement of miR-877-3p in CC, its expression was mea-
sured by quantitative PCR (qRT-PCR) in a series of 46 SCCCs, 38 HSILs, and 20 BLs.
We observed a very significant overexpression in tumors compared with BLs (p < 0.001)
(Table 1 and Figure 1A). Furthermore, the clinical value of miR-877-3p expression was
examined in SCCC. Several cut-off points were used to stratify patients according to their
miR-877-3p levels, such as Youden’s index, the mean and median, and the 75th percentile
of the series. Although no significant associations with survival were found, SCCC patients
with higher miR-877-3p levels tended to have a worse prognosis than those with a lower
level of expression, regardless of the cut-off value (Figure 1B). These findings suggested
that miR-877-3p could have a biological role in SCCC.
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Table 1. Distribution of miR-877-3p expression in our series of cervical samples. Number and
percentage of patients with miR-877-3p levels below and above the median expression of the whole
series. (BL: benign lesion of the cervical epithelium; HSIL: high-grade squamous intraepithelial
lesion; SCCC: squamous cell carcinoma of the cervix; NA: not analyzable due to small quantity or




BL 18 (78%) 2 (9%) 3 (13%)
HSIL 20 (48%) 18 (43%) 4 (9%)
SCCC 14 (27%) 32 (62%) 6 (11%)
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Figure 1. miR-877-3p in cervical tissues. (A) miR-877-3p expression was measured by quantitative PCR in a series of 104 
lesions of the cervical epithelium with varying degrees of severity. (*** p < 0.001; RQ, relative quantification). (B) SCCC 
patients were stratified according to the level of miR-877-3p expression (overall median of the whole series of benign 
lesions (BLs), high-grade squamous intraepithelial lesions (HSILs), and squamous cell carcinomas of the cervix (SCCCs)). 
No significant associations were found between the miR-877-3p expression profile and progression-free or overall sur-
vival. 
2.2. miR-877-3p Silencing Is Not Critical for CC Cell Proliferation 
To determine the biological role of miR-877-3p in SCCC, functional experiments were 
carried out in two cell lines. miR-877-3p levels were measured in C-33A and SiHa cells by 
qRT-PCR, and found to be expressed at higher levels (Figure 2A) than BLs. Therefore, a 
knockdown strategy was employed by using a Cy3-labelled scramble negative control 
anti-miR (NC) and an anti-miR-877-3p. Flow cytometry showed that transfection effi-
ciency was greater than 96% in all cell lines (Figure 2B). Concomitantly, a time- and dose-
dependent decrease in miR-877-3p levels was found by qRT-PCR upon anti-miR-877-3p 
transfection (data not shown), with more than 90% knockdown being achieved after 4 
days (Figure 2B). This silencing affected cell proliferation in C-33A cells, but not in SiHa 
cells (Figure 2C). Effects of miR-877-3p inhibition were also analyzed in the HeLa cell line, 
which was derived from an HPV18-positive cervical adenocarcinoma, with clinical fea-
tures nearly identical to those of SCCC [50]. Although HeLa cells had lower levels of miR-
877-3p than did SCCC-derived cell lines (Figure S1A), the transfection efficiencies were 
very similar (Figure S1B), and no effect on HeLa cell proliferation was observed upon 
miR-877-3p inhibition (Figure S1C). 
Figure 1. miR-877-3p in cervical tissues. (A) miR-877-3p expression was measured by quantitative PCR in a series of 104
lesions of t e cer ical e it eliu ith arying egrees f se erit . (*** p 0.001; , relati e a tificati ). ( )
ati t stratified ac ording to the lev l of miR-877-3p expression ( verall median of the whole series of b nign l sions
(BLs), high-grade squamous intraepi helial lesions (HSILs), and squamous cell carcinomas of the cervix (SCCCs)). No
significant associations were found between the miR-877-3p expression profile and progression-free or overall survival.
2.2. miR-877-3p Silencing Is Not Critical for CC Cell Proliferation
To determine the biological role of miR-877-3p in SCCC, functional experiments were
carried out in two cell lines. miR-877-3p levels were measured in C-33A and SiHa cells
by qRT-PCR, and found to be expressed at higher levels (Figure 2 ) than BLs. There-
fore, a knockdown strategy was employed by using a Cy3-labelled scramble negative
control anti-miR (NC) and an anti-miR-877-3p. Flow cytometry showed that transfection
efficiency was greater tha 96% in all cell lines (Figure 2B). Concomitantly, a time- and dose-
d pendent d cr ase i miR-877-3p levels was found by qRT-PCR upon anti-miR-877-3p
transfection (dat not shown), with more than 90% knockdown being achieved after 4 days
(Figure 2B). This silencing affected cell proliferation i C-33A cells, but not in SiHa cells
(Figure 2C). Effects of miR-877-3p inhibition were also analyzed in the HeLa cell line, which
wa derived from an HPV18-positive cervical adenocarcin ma, with cli ical features nearly
identical to those of SCCC [50]. Although HeLa cells had lowe levels of miR-877-3p th n
did SCCC-derived cell lines (Figure S1A), the transfection efficiencies ere ry si lar
(Figure S1B), and no eff ct on HeLa cell proliferation was ob erved upon miR-877-3p
inhibition (Figure S1C).
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Figure 2. miR-877-3p inhibition in squamous cell carcinoma of the cervix (SCCC) cell lines. (A) miR-877-3p expression was 
measured by quantitative PCR in C-33A and SiHa cells. (B) SCCC cells were transfected with a Cy3-labelled negative 
control anti-miR (NC) and an anti-miR-877-3p. Transfection and knockdown efficiencies were checked by flow cytometry 
(left panel) and quantitative PCR (right panel), respectively. (C) Effect of miR-877-3p silencing on SCCC cell proliferation 
was analyzed after a 4-day transfection by staining cells with crystal violet and measuring the absorbance at 590 nm. 
Images were acquired at 50× magnification. (* p < 0.05; RQ, relative quantification). 
As no major differences were found in cell proliferation, with the exception of the C-
33A cell line, we explored other processes relevant to cell survival, such as apoptosis induc-
tion, changes in the distribution of cell cycle phases, and p16 expression regulation, which 
has been reported to be activated by miR-877-3p in bladder cancer [44]. Again, no cell re-
sponse was consistently modulated by miR-877-3p inhibition (Figure S2), indicating that 
miR-877-3p did not mainly affect cell survival pathways in CC. 
2.3. miR-877-3p Silencing Impairs CC Cell Migration and Invasion 
We wondered whether miR-877-3p could be involved in later events in SCCC progres-
sion. After anti-miR-877-3p transfection, a 2-day wound-healing assay showed that miR-
877-3p inhibition significantly impaired C-33A and SiHa cell migration (Figure 3A). We ob-
served that cell invasion ability was almost completely abolished in both cell lines after miR-
877-3p knockdown (Figure 3B). Very similar results regarding cell migration (Figure S1D) 
and invasion (Figure S1E) were observed in the HeLa cell line. These findings demonstrate 
that miR-877-3p is necessary for the acquisition of aggressive properties in CC, and highlight 
its potential as a therapeutic target in CC. 
Figure 2. iR-877-3p inhibition in squamous cell carcinoma of the cervix (SCCC) cell lines. (A) miR-877-3p expression
was measured by quantitative PCR in C-33A and SiHa cells. (B) SCCC cells were transfected with a Cy3-labelled negative
control anti-miR (NC) and an anti-miR-877-3p. Transfection and knockdown efficiencies were checked by flow cytometry
(left panel) and quantitative PCR (right panel), respectively. (C) Effect of miR-877-3p silencing on SCCC cell proliferation
was analyzed after a 4-day transfection by staining cells with crystal violet and measuring the absorbance at 590 nm. Images
were acquired at 50×magnification. (* p < 0.05; RQ, relative quantification).
As no major differences were found in cell proliferation, with the exception of the
C-33A cell line, we explored other processes relevant to cell survival, such as apoptosis
induction, changes in the distribution of cell cycle phases, and p16 expression regulation,
which has been reported to be activated by miR-877-3p in bladder cancer [44]. Again, no
cell response was consistently modulated by miR-877-3p inhibition (Figure S2), indicating
that miR-877-3p did not mainly affect cell survival pathways in CC.
2.3. miR-877-3p Silencing Impairs CC Cell igration and Invasion
e ondered whether miR-877-3p could be involved in later events in SCCC pro-
gression. After anti-miR-877-3p transfection, a 2-day wound-healing assay showed that
miR-877-3p inhibition significantly impaired C-33A and SiHa cell migration (Figure 3A).
We observed that cell invasion ability was almost completely abolis ed in both cell lines
after miR-877-3p knockdown (Figure 3B). Very similar results regarding cell migration
(Figure S1D) and invasion (Figure S1E) were observed in the HeLa cell line. These fi dings
demonstrate that miR-877-3p is necessary for the acquisition of aggressive properties in
CC, and highlight its otenti l as a therapeutic target in CC.
Cancers 2021, 13, 1739 6 of 26




Figure 3. Effects of miR-877-3p inhibition on squamous cell carcinoma of the cervix cell migration and invasion. (A) C-
33A and SiHa cells were transfected with the negative control anti-miR (NC) and the anti-miR-877-3p for 4 and 18 days, 
respectively, to reach nearly confluence, and cell migration ability was assessed 2 days later with a wound-healing assay. 
The migration index was calculated as the scratch width at first day minus that at +2 days. Images were acquired at 50× 
magnification. (B) C-33A and SiHa cells were transfected with the NC and the anti-miR-877-3p for 4 days. Cell invasion 
capacity was measured as the ability to penetrate a Matrigel® layer over 3 days. Images were acquired at 50× magnification. 
(* p < 0.05; ** p < 0.01; *** p < 0.001). 
2.4. The ZNF177 Gene Is a Direct Target of miR-877-3p 
Two strategies were used to gain insight into the miR-877-3p molecular mechanism. 
First, in silico target prediction was analyzed using the TargetScan v7.1 database 
(http://www.targetscan.org/) [51] (accessed on April 2016). Of all the predicted targets, the 
zinc finger protein 177 (ZNF177) gene was selected because it has been described as being 
epigenetically silenced in other tumor types [52–54], including gynecological cancers 
[55,56]. Therefore, ZNF177 expression was measured by qRT-PCR in our series of cervical 
tissues. Interestingly, a higher level of ZNF177 was found in BLs than in cervical tumors, 
HSILs, and SCCCs (Figure 4A), suggesting that there is an inverse relationship with miR-
877-3p expression (Table 1 and Figure 1A). Notably, we identified a potential binding site 
of miR-877-3p at 623–643 bp of the ZNF177 gene 3′UTR region. To demonstrate their func-
tional interaction, two 3′UTR regions of the ZNF177 gene were cloned into the pGL3-con-
trol luciferase reporter vector: one with an intact potential binding site (wild type, wt 
3′UTR), and another with six nucleotides mutated at the binding site (mut 3′UTR) to 
weaken the binding (Figure 4B). After transfection into 293T cells, we found that the anti-
miR-877-3p was able to significantly induce luciferase expression compared with the NC, 
and that the increase was more pronounced in the wt 3′UTR than in the mut 3′UTR (Figure 
4C). Accordingly, upregulation of the ZNF177 protein level was observed by western blot 
in CC cell lines upon miR-877-3p knockdown (Figure 4D), indicating that ZNF177 expres-
sion is negatively regulated by miR-877-3p. Furthermore, ZNF177 overexpression (Figure 
4E) did not affect SCCC cell proliferation (Figure 4F), but significantly impaired cell mi-
gration ability in both C-33A and SiHa cell lines (Figure 4G), as miR-877-3p inhibition did 
Figure 3. Effects of miR-877-3p i hibition on squamous cell carcinoma of the cervix cell migration
and invasion. (A) C-33A and SiHa cells wer transfected with the negative co rol anti-miR (NC) and
the anti-miR-877-3p for 4 and 18 days, respectively, to reach nearly confluence, and cell migration
ability was assessed 2 days later with a wound-healing assay. The migration index was calculated
as the scratch width at first day minus that at +2 days. Images were acquired at 50×magnification.
(B) C-33A and SiHa cells were transfected with the NC and the anti-miR-877-3p for 4 days. Cell
invasion capacity was measured as the ability to penetrate a Matrigel® layer over 3 days. Images
were acquired at 50×magnification. (* p < 0.05; ** p < 0.01; *** p < 0.001).
2.4. The ZNF177 Gene Is a Direct Target of miR-877-3p
Two strategies were used to gain insight into the miR-877-3p molecular mechanism.
First, in silico target prediction was analyzed using the TargetScan v7.1 database (http:
//www.targetscan.org/) [51] (accessed on April 2016). Of all the predicted targets, the
zinc finger protein 177 (ZNF177) gene was selected because it has been described as being
epigenetically silenced in other tumor types [52–54], including gynecological cancers [55,56].
Therefore, ZNF177 expression was measured by qRT-PCR in our series of cervical tissues.
Interestingly, a higher level of ZNF177 was found in BLs than in cervical tumors, HSILs,
and SCCCs (Figure 4A), suggesting that there is an inverse relationship with miR-877-3p
expression (Table 1 and Figure 1A). Notably, we identified a potential binding site of miR-
877-3p at 623–643 bp of the ZNF177 gene 3′UTR region. To demonstrate their functional
interaction, two 3′UTR regions of the ZNF177 gene were cloned into the pGL3-control
luciferase reporter vector: one with an intact potential binding site (wild type, wt 3′UTR),
and another with six nucleotides mutated at the binding site (mut 3′UTR) to weaken the
binding (Figure 4B). After transfection into 293T cells, we found that the anti-miR-877-3p
was able to significantly induce luciferase expression compared with the NC, and that
the increase was more pronounced in the wt 3′UTR than in the mut 3′UTR (Figure 4C).
Accordingly, upregulation of the ZNF177 protein level was observed by western blot in
CC cell lines upon miR-877-3p knockdown (Figure 4D), indicating that ZNF177 expression
is negatively regulated by miR-877-3p. Furthermore, ZNF177 overexpression (Figure 4E)
did not affect SCCC cell proliferation (Figure 4F), but significantly impaired cell migration
ability in both C-33A and SiHa cell lines (Figure 4G), as miR-877-3p inhibition did (Figure 3A).
Collectively these findings suggest a functional link between miR-877-3p and ZNF177.
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Figure 4. ZNF177 expression in cervical cancer. (A) ZNF177 mRNA levels were measured by quantitative PCR in a series 
of 108 cervical malignancies. Horizontal lines show the median of each series. (RQ, relative quantification). (B) A putative 
binding site of the miR-877-3p was found in the 3′ untranslated region (3′UTR) region of the ZNF177 gene. Two 3′UTR 
regions were synthesized: one with the intact binding site (wild type, wt), and one with six mutated nucleotides (in red) 
from the binding site (mut), to weaken the potential binding to miR-877-3p. (C) 293T cells were transfected with both the 
pGL3-control luciferase reporter vector containing the firefly luciferase gene with either the wt or the mut 3′UTR of the 
ZNF177 gene, and the Renilla firefly reporter vector, along with the negative control anti-miR (NC) or the anti-miR-877-
3p. Luminescence was measured 3 days later. (D) ZNF177 protein levels were examined in CC cell lines upon miR-877-3p 
silencing, and α-tubulin was used as a loading control. Numbers indicate the ratio of ZNF177 to α-tubulin intensity as-
sessed by densitometry. (E) Efficiency of ZNF177 overexpression in C-33A and SiHa cells was measured by quantitative 
PCR in untransfected cells (MOCK), cells transfected with the empty vector pcDNA3.1 (EMPTY), and cells transfected 
with the pcDNA3.1 + ZNF177 construction (ZNF177). (F) 0.5 × 106 untransfected and transfected cells with the empty 
vector and the vector + ZNF177 construction were seeded and allowed to grow for 72 h. They were then trypsinized and 
viable cells were counted by using the Trypan blue exclusion test. (G) Equally transfected cells were seeded and allowed 
to almost reach confluence. After 8 h fetal bovine serum (FBS)-starvation, 3 scratches were performed on the cell mono-
layer, and cells were allowed to migrate to heal the wound for 48 h in the presence of 5% FBS. Migration index was 
calculated as the scratch width at 0 h minus that at 48 h. All images were acquired at 100× magnification. (H) Nuclear and 
cytoplasmic ZNF177 protein levels were evaluated by immunohistochemistry in 98 cervical malignancies (23 benign le-
sions (BLs), 33 high-grade squamous intraepithelial lesions (HSILs), and 42 squamous cell carcinomas of the cervix 
(SCCCs)). (I) Association between cytoplasmic ZNF177 expression levels and progression-free survival in SCCC patients. 
(J) Multivariate analysis showing almost significant independence of cytoplasmic ZNF177 expression as a potential prog-
nostic biomarker in SCCC (p = 0.059). (CI, confidence interval) (* p < 0.05; ** p < 0.01; *** p < 0.001). 
Figure 4. ZNF177 expression in cervical cancer. (A) ZNF177 mRNA le els were m asured by
quantitative PCR in a series of 108 cervical malignancies. Horizontal lines show the median of each
series. (RQ, relative quantification). (B) A putative binding site of the miR-877-3p was found in the 3′
untranslated region (3′UTR) region of the ZNF1 gene. Two 3′UTR regions were synthesized: one
with the intact binding site (wild type, wt), and one with six mutated nucleotides (in red) from the
binding site (mut), to we ken the potential binding to miR-877-3p. (C) 293T cells were transfected
with both the pGL3-control luciferase reporter vector containing the firefly luciferase gene with
either the wt or the mut 3′UTR of the ZNF177 gene, and the Renilla firefly reporter vector, along
with the negative control a ti-miR (NC or the anti-miR-877-3p. Lumines nce was measured 3 days
later. (D) ZNF177 protein levels were examined in CC cell lines upon miR-877-3p silencing, and
α-tubulin was used as a loading control. Numbers indicate the ratio of ZNF177 to α-tubulin intensity
assessed by densitometry. (E) Efficiency of ZNF177 overexpression in C-33A and SiHa cells was
measured by quantitative PCR in untransfected cells (MOCK), cells transfected with the empty vector
pcDNA3.1 (EMPTY), and cells tr nsfected with the pcDNA3.1 + ZNF177 construction (ZNF177).
(F) 0.5 × 106 untransfected and transfected cells with the empty vector and the vector + ZNF177
construction were seeded and allowed to grow for 72 h. They were then trypsinized and viable cells
were counted by using the Trypan blue exclusion test. (G) Equally transfected cells were seeded and
allowed to almost reach confluence. After 8 h fetal bovine serum (FBS)-starvation, 3 scratches were
performed on the cell monolayer, and cells were allowed to migrate to heal the wound for 48 h in
the presence of 5% FBS. Migration index was calculated as the scratch width at 0 h minus that at
48 h. All images were acquired at 100× magnification. (H) Nuclear and cytoplasmic ZNF177 protein
levels were evaluated by immunohistochemistry in 98 cervical malignancies (23 benign lesions (BLs),
33 high-grade squamous intraepithelial lesions (HSILs), and 42 squamous cell carcinomas of the
cervix (SCCCs)). (I) Association between cytoplasmic ZNF177 expression levels and progression-
free survival in SCCC patients. (J) Multivariate analysis showing almost significant independence
of cytoplasmic ZNF177 expression as a potential prognostic biomarker in SCCC (p = 0.059). (CI,
confidence interval) (* p < 0.05; ** p < 0.01; *** p < 0.001).
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Additionally, ZNF177 expression was explored in tissues from cervical malignan-
cies. Although this protein has been little researched, it is predicted to be a transcription
factor due to its zinc-finger structure. First, we examined its nuclear expression, and
found that it dropped significantly as the severity of the lesion increased from BL to SCCC
(Figure 4H, Figure S3, and Table 2). Importantly, we noticed that cytoplasmic ZNF177
levels were significantly higher in cervical tumors than in BLs. This observation suggested
that ZNF177 expression and subcellular location could be used as diagnostic biomarkers
to distinguish HSIL from SCCC. In fact, as shown in Figure S4, there was a significant
correlation between nuclear but not cytoplasmic ZNF177 levels and the type of cervi-
cal lesion (R2 = 0.9859, p = 0.01; and R2 = 0.0453, p = 0.667, respectively). Intriguingly,
SCCC patients with some cytoplasmic ZNF177 expression (although at a low level) had
a very significantly worse prognosis than those with no cytoplasmic ZNF177 (p = 0.002)
(Figure 4I) and tended to have worse overall survival too, although statistical significance
was not reached (p = 0.079) (Figure S5). This finding highlighted the value of cytoplasmic
ZNF177 expression as a potential prognostic biomarker in SCCC, representing a four-fold
increase in the risk of relapse almost regardless of other clinical characteristics relevant
to SCCC progression (p = 0.059), such as age, stage and vascular invasion (Figure 4J).
Furthermore, a preliminary estimation of the accuracy of ZNF177 subcellular location to
predict prognosis and diagnosis in CC was performed. Figure S6 shows good sensitivity
and specificity, with area under the curve of 0.767 and 0.838 for prognosis and diagnosis,
respectively (p ≤ 0.001). While aware of the low number of cases studied, these results
indicate that cytoplasmic ZNF177 expression and subcellular location could be used to
predict diagnosis and prognosis in cervical malignancies.
Table 2. Distribution of ZNF177 protein expression and subcellular location in our series of cervical
tissues. Number and percentage of patients with negative (0), low (1), moderate (2), and high
(3) levels of expression of nuclear and cytoplasmic ZNF177 protein levels, showing a very significant
association with the cervical lesion type (p = 0.001 and 0.004, respectively). (BL: benign lesion of
the cervical epithelium; HSIL: high-grade squamous intraepithelial lesion; SCCC: squamous cell
carcinoma of the cervix; NA: not analyzable due to limited representativeness of the tissue slice).
Cervical
Tissue
Nuclear ZNF177 Cytoplasmic ZNF177


























































2.5. miR-877-3p Is Involved in Regulating Cytoskeletal Protein Folding
In parallel, we used a second strategy to understand the mechanism of action of
miR-877-3p, based on the exhaustive characterization of the proteostatic impairment in-
duced by miR-877-3p knockdown. Given the importance of ZNF177 subcellular location,
cytoplasmic, and nuclear proteomes of NC-transfected and anti-miR-877-3p-transfected
SCCC cells were separately extracted and compared by liquid chromatography-tandem
mass spectrometry (LC–MS/MS) (Table S1). Since no striking changes in protein shuttling
between subcellular components were found, data from both fractions were integrated as
whole-cell proteomes. Thus, 180 and 114 human proteins were found to be significantly
altered upon miR-877-3p knockdown in C-33A and SiHa cell lines, respectively (p < 0.05)
(Tables S2 and S3). Notably, no HPV16 protein was detected in SiHa cells. Overall, pro-
tein upregulation was a more frequent event than protein downregulation (92 and 76
upregulated vs. 78 and 38 downregulated proteins in C-33A and SiHa, respectively). All
differentially expressed proteins in each cell line were clustered into two major biological
groups, one involving protein synthesis, and the other linking chaperones and cytoskeletal
proteins. These functions were retrieved using several bioinformatic tools, such as STRING
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(Figure S7), Ingenuity Pathway Analysis (Tables S4 and S5, and Figure S8), and Metascape
(Figure 5A). When data from the two cell lines were combined, the most significant clusters
were protein translation and formation of tubulin folding intermediates by the chaperonin-
containing T-complex protein 1 (CCT) complex (Figure 5A). To identify which proteins
were involved in these processes, the 22 proteins that were simultaneously altered by
miR-877-3p in both cell lines (Figure 5B) were integrated in a network, which highlighted
a strong functional interaction between CCT3 and HSP90AA1 chaperones, and TUBB4B
and TUBB cytoskeletal proteins (Figure 5C). Finally, two proteins were selected to validate
these results: GPC1, which displayed the greatest change, and CCT3, which seemed to play
a central role in miR-877-3p pathway. In accordance with the data-mining analysis, GPC1
and CCT3 protein expression decreased and increased, respectively, upon miR-877-3p
silencing, especially in SiHa cells (Figure 5D). These findings confirm that miR-877-3p reg-
ulates cytoskeletal protein folding, which would explain the impairment of cell migration
and invasion observed when it is knocked down.
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Figure 5. Integration of proteins significantly deregulated by miR-877-3p in both squamous cell carcinoma of the cervix
(SCCC) cell lines. (A) Proteins simultaneously altered by miR-877-3p in C-33A and SiHa cell lines were functionally clustered
by the Metascape tool. Details are provided for the most significant terms: formation of tubulin folding intermediates
by CCT/TRiC complex and protein translation. (B) Heat-maps showing all proteins that were significantly altered by
anti-miR-877-3p in each cell line (left panel), and the 22 commonly altered proteins in both cell lines (right panel). Black
arrows highlight CCT3 and GPC1 proteins, which were selected for further validation. Scale bars represent log2-fold
change. Blue color indicates proteins that shuttled from the nucleus to the cytoplasm in C-33A, or from the cytoplasm to
the nucleus in SiHa. (C) Network of the 22 proteins commonly deregulated by the anti-miR-877-3p in both C-33A and
SiHa cell lines. The blue circle highlights the strong link between chaperones and cytoskeletal proteins. (D) Western blots
showing decreased and increased levels of GPC1 and CCT3 protein levels, respectively, in SCCC cells upon miR-877-3p
inhibition. An image of the whole stain-free gel was used to check protein loading; no antibody was employed for this
purpose because most of them detect cytoskeletal proteins or metabolic enzymes like GAPDH, which appeared here as
a differentially expressed protein. Numbers indicate the intensity of each band relative to that of the loaded protein, as
measured by densitometry.
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2.6. miR-877-3p Knockdown Synergizes with Paclitaxel
In view of the disruption of cytoskeletal protein folding driven by the miR-877-
3p, we examined whether these effects could be enhanced by paclitaxel, a microtubule-
stabilizing drug commonly administered to SCCC patients [2]. To this end, first, half
maximal inhibitory concentration (IC50) values of paclitaxel were calculated at 72 h. As
seen in Figure S9, paclitaxel was very effective in all CC cell lines in the low nanomolar
range. SCCC cells were then simultaneously subjected to miR-877-3p silencing and sub-
IC50 paclitaxel treatment for 24, 48, and 72 h. We observed a noticeable change in cell
morphology (Figure 6A), and a significant drop in cell viability (Figure 6B) and especially
in cell migration (Figure 6C) in SCCC cells. Similar though smaller magnitude results were
observed in the HeLa cell line (Figure S10). Importantly, all these effects were significantly
enhanced relative to single miR-877-3p knockdown or paclitaxel administration. The
observed inhibitory effect of the combination was greater than the expected one (Table 3),
indicating that the double-targeting of cytoskeletal proteins had a synergistic effect on CC
cell viability and migration.
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Figure 6. Simultaneous miR-877-3p inhibition and paclitaxel treatment in squamous cell carcinoma of the cervix cell lines.
Anti-miR-877-3p transfection and sub-IC50 paclitaxel treatment were performed in C-33A and SiHa cells. Effects on cell
morphology, viability, and migration were monitored for 24, 48 and 72 h. (A) Images were acquired at 200×magnification
after 72 h of miR-877-3p silencing and paclitaxel treatment. (B) C-33A and SiHa cell viabilities were measured after
72 h of double-targeting as the intracellular ATP content. (C) C-33A and SiHa cell migration was examined 48 h after
double-targeting. The migration index was calculated as the scratch width at time 0 minus that at 48 h. (* p < 0.05; ** p < 0.01;
*** p < 0.001).
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Table 3. Nature of the anti-miR-877-3p + paclitaxel combination in CC cell lines. Inhibitory effect on CC cell viability, calculated
as 1 minus the proportion of viable cells in silenced or treated cells vs. NC- and DMSO-treated cells, represented in Figure 6B
and Figure S10B. Inhibitory effect on CC cell migration ability, calculated as 1 minus the proportion of migration index in
silenced or treated cells vs. NC- and DMSO-treated cells, represented in Figure 6C and Figure S10C. The predicted effect of
the combination (PEcombination) was calculated as: PEcombination = OEanti-miR-877-3p + OEpaclitaxel − OEanti-miR-877-3p × OEpaclitaxel;
where OEanti-miR-877-3p is the observed effect of the anti-miR-877-3p; and OEpaclitaxel is the observed effect of paclitaxel.
Effect Drug
C-33A SiHa HeLa
NC anti-miR-877-3p NC anti-miR-877-3p NC anti-miR-877-3p
Cell viability
DMSO 0.00 0.18 0.00 0.24 0.00 0.17
Paclitaxel 0.67 0.67 0.16 0.40 0.14 0.36
PEcombination 0.73 0.37 0.29
Cell migration
DMSO 0.00 0.54 0.00 0.77 0.00 0.23
Paclitaxel 0.92 1.52 0.26 1.10 −0.17 0.97
PEcombination 0.96 0.83 0.09
3. Discussion
Clinical management of cervical cancer is still limited because of the lack of molecular
biomarkers that could help clinicians diagnose, provide a prognosis and propose new
targeted therapies [2–5], especially for SCCC, which represents 70–80% of all CC cases [2].
A better understanding of the molecular mechanisms that underlie SCCC development
would allow us to identify the biomarkers we need to improve the dismal expectancies of
these patients [2,18,29]. Among the molecular aberrations that arise during SCCC patho-
genesis, miRNAs have attracted increasing attention, because they affect the expression of
tumor-suppressor genes or oncogenes, which in turn, alter multiple biological processes,
such as cell maturation, differentiation, proliferation, cell cycle, migration, invasion, au-
tophagy, apoptosis, adhesion, and metastasis [29]. Aberrantly expressed miRNAs in CC
patients compared with healthy women have been extensively reported [28,57], and some
of them have been proposed as biomarkers of potential use in CC diagnosis [25–27,58], prog-
nosis [19,22,29,30,59] or response to radiotherapy [60–62] and chemotherapeutic agents,
such as cisplatin [63,64], and paclitaxel [65]. Here, we focused on miR-877 because of its
association with processes relevant to SCCC, such as p16 activation [3,4], restoration of
paclitaxel sensitivity [2], and TLR4 inhibition [46–49], in bladder cancer [44], hepatocellular
carcinoma [32], and glioma [43], respectively. Our results demonstrate that miR-877-3p
is overexpressed in tumoral samples relative to BLs and, for the first time, provide evi-
dence of the contribution of miR-877-3p in SCCC progression. Very recently, it has been
described that the miR-877-5p strand may play an anti-tumor role in CC [66], because it
is downregulated in CC tissues, and its overexpression decreased CC cell proliferation
and invasion [67]. In spite of the apparent controversy between this recent report and our
results, it is important to note that the mature 5p and 3p strands of the same miRNA can
participate in different cell signaling pathways, and then have distinct effects [68,69].
Although miR-877-3p silencing did not seem to affect CC cell proliferation, apoptosis
induction, or cell cycle deregulation, we observed that miR-877-3p had a major role in CC
cell migration and invasion, processes associated with the later stages of cancer progression.
Similarly, miR-877-3p did not influence p16 expression in SCCC, unlike what has been
observed in bladder cancer [44]. Since p16 is an essential cell-cycle regulator in cervical
carcinogenesis [3,4,70,71], the lack of association between miR-877-3p expression and p16
levels strengthened the idea that miR-877-3p was not involved in the early stages of SCCC
development. Likewise, miR-20a [72,73] and miR-218 [74] were found to promote CC
cell migration and invasion without affecting cell viability. In fact, although the evidence
points to a role for miRNAs at every stage of CC initiation and development [22], many
miRNAs have very recently been linked to aggressiveness in CC [75–83], although their
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complex molecular pathways have not been fully elucidated. Here, we have used two
strategies to explore the mechanism of action of miR-877-3p in SCCC: in silico-predicted
target examination and comprehensive identification of proteins whose expression changed
in vitro upon miR-877-3p inhibition. In spite of the large amount of data these approaches
can produce, it is important to note that they also have limitations: on the one hand, in silico
prediction is based on the complementarity between miRNA and target 3′UTR sequences,
and therefore requires careful validation. On the other hand, for technical reasons, only
the most abundant proteins can be explored by our LC–MS/MS approach. Consequently,
miR-877-3p targets other than those reported in this study might also be active in its
molecular pathway. For instance, no HPV16 protein was detected in our experiments in
miR-877-3p-silenced SiHa cells, probably because of its lower relative abundance compared
with human proteins. However, a link between miR-877-3p and HPV16 cannot be ruled
out.
Some reports have shed light on miRNA machinery by identifying the particular pro-
tein targets responsible for cancer-cell aggressiveness. For example, the tumor-suppressor
miR-218 targeted LAMB3, a laminin-332 component of the basement membrane which
influences cell adhesion, migration and invasion in SCCC [74] through cytoskeleton orga-
nization [84]. Then, disassembly of cytoskeletal structures, which is crucial for gaining cell
motility and initiating metastasis [85], can also be controlled by miRNAs. Consistent with
this, we show that miR-877-3p promoted CC cell migration and invasion by modulating
the folding of cytoskeletal proteins, mainly through the CCT complex, also known as the
TCP-1 ring complex (TRiC). CCT/TRiC is a chaperone complex, comprising eight subunits
(CCT1-8), which is required for the folding of newly synthesized actin and tubulin, and is
thus linked to all cellular processes involving microtubules and actin filaments, such as cell
division, migration, and invasion, which are major drivers of cancer progression [86–88].
The contribution of CCT/TRiC to cancer has not received much attention, but evidence of
it is now emerging, since it also mediates the folding and function of client proteins related
to oncogenesis, such as the Von Hippel-Lindau and p53 tumor-suppressor proteins, the
telomerase cofactor TCAB1 and STAT3 oncoproteins, and several cell cycle regulators [88].
The disrupted folding activity of CCT/TRiC can result in altered proteostasis, leading to
loss or toxic gain of function of the misfolded substrates. It has been suggested that each
CCT subunit has specific substrates and, therefore, different functions [88,89]. For instance,
CCT8 regulates cell proliferation, migration and invasion in several tumors [90–93]; CCT2
inhibition reduces cell migration in tubulin-binding agent-resistant tumors [88,94–96]; and
CCT3 supports cell proliferation in hepatocellular carcinoma [97]. Based on our findings,
the anti-miR-877-3p increased CCT3 expression in SCCC, leading to an anomalous fold-
ing of actin and tubulin, which impaired both cell migration and invasion. Accordingly,
although only one CCT subunit, CCT6A, has been found among the miR-877-3p in silico
predicted targets in the TargetScan database (most recently accessed in March, 2021), we
did find among them some cytoskeletal proteins, such as ACTC1 (actin, alpha cardiac mus-
cle 1), ACTRT3 (actin-related protein T3), PHACTR2 (phosphatase and actin regulator 2),
PHACTR3 (phosphatase and actin regulator 3), ACTN1 (alpha-actinin-1), LAMC3 (laminin
subunit gamma-3), and TUBB6 (tubulin beta-6 chain). Since microtubules are already the
target of therapies such as paclitaxel, it has been suggested that inhibiting CCT-tubulin
interactions, and then tubulin folding, may enable new therapeutic strategies for treating
tumors that have developed resistance to paclitaxel [86]. In fact, we demonstrate that
miR-877-3p silencing synergistically enhances the effects on CC cell viability and, above all,
cell migration induced by paclitaxel, one of the most common drug for SCCC patients [2].
It is well established that paclitaxel commonly induces mitotic arrest [98,99], so low doses
were used here to avoid massive cell detachment and loss of cell monolayer in our attempt
to measure migration ability, as previously reported [100,101]. Even at sub-IC50 doses of
paclitaxel, the reduction of CC cell migration is synergistically potentiated by miR-877-3p
depletion. Therefore, our results highlight the relevance of cytoskeleton-targeting as an
effective therapeutic strategy in CC, and suggest that knocking down miR-877-3p could
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improve therapeutic response and reduce potential toxicity and side effects by allowing a
lower paclitaxel dose to be administered.
Almost half the patients who are diagnosed with locally advanced CC have an un-
favorable response to conventional treatments based on cisplatin and paclitaxel [1,2,102].
A growing body of evidence has shown that miRNA manipulation may be beneficial for
CC treatment. Thus, the therapeutic development of miRNA mimics (to recover tumor-
suppressor miRNA levels) or inhibitors (to repress onco-miR expression) may facilitate
novel therapies and improve CC prognosis [22,25], as did miR-26a, miR-31, and miR-34a
delivery in liver, breast, and advanced solid tumors, respectively [26,30]. Regarding CC,
in vivo miR-143 or miR-34 supplementation, as well as miR-21 inhibition, reduce metastatic
potential, and so have been proposed as useful therapeutic strategies [25]. In the present
study, we also propose miR-877-3p as a potential therapeutic target in CC, since we have
demonstrated that its inhibition diminishes cell migration and invasion and improves
response to paclitaxel in vitro. Further research is required to test the effects of miR-877-3p
silencing alone and combined with paclitaxel in in vivo CC models.
Since miRNA deregulation plays a key role in CC malignant transformation, there
has been increasing interest not only in miRNAs per se, but also in their targets, since
both can be exploited in the clinical setting [22]. We have experimentally verified that the
ZNF177 gene is directly targeted and repressed by miR-877-3p, and that is functionally
involved in the effects on cell migration driven by miR-877-3p. As an in silico predicted
target of miR-877-3p, ZNF177 has been little investigated. A few cancer types are known
to exhibit epigenetic inhibition of ZNF177 expression. In particular, a higher frequency of
aberrant DNA methylation of its promoter has been reported in endometrial [55], lung [52],
hepatocellular [53], and gastric [54] cancers compared with their non-tumoral counterparts.
Indeed, ZNF177 is part of the signature of hypermethylated genes of diagnostic value
in early stages of lung [52] and breast cancer [56]. Similarly, we have established the
clinical importance of assessing ZNF177 expression and subcellular location in cervical
malignancies, whose clinical management urgently needs molecular biomarkers for an
accurate prognosis and diagnosis [2,5], differentiating HSIL and SCCC cases [8,9]. Im-
portantly, ZNF177 expression and subcellular location effectively distinguish HSIL from
SCCC. This is the first report of a molecular biomarker that could be useful in cervical
tumor diagnosis, which otherwise currently depends on the subjective assessment of tissue
morphology [2–5]. We also highlight the importance of ZNF177 subcellular location in
predicting poor prognosis in SCCC. Although the borderline statistical significance did
not establish cytoplasmic ZNF177 as an independent prognostic biomarker in our series
(p = 0.059), further research in a larger cohort of patients might confirm its independent
value. The vast majority of molecular biomarkers currently used in clinical practice are
based on the aberrant levels of some proteins (mostly presence/absence, such as hormone
receptor and HER2 in breast cancer [10]), rather than on their subcellular location. How-
ever, regardless of expression levels, if a protein is not located where it should exert its
activity, it may not function properly. Therefore, changes in protein location could be also
considered as molecular alterations, and thus, potential biomarkers. Indeed, we [103],
and others [104–109], have reported the likely clinical relevance of the subcellular location
of some proteins in several tumors. Similarly, we emphasize here for the first time the
relevance of the subcellular location of ZNF177 as a potential diagnostic and prognostic
biomarker in SCCC. Nevertheless, the likely value of ZNF177 as biomarker needs to be
confirmed in larger cohorts of patients.
4. Materials and Methods
4.1. Patient Samples
A series of 117 formalin-fixed, paraffin-embedded (FFPE) samples from women diag-
nosed with SCCC (n = 52), HSIL (n = 42) and BL (n = 23), with International Classification
for Oncology codes 8070/3, 8077/2, and 8052/0, respectively, was analyzed. All patients
were diagnosed between 1995 and 2015 in the Pathology Departments of the Complejo Hos-
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pitalario de Navarra (Pamplona, Spain), Hospital Universitari de Bellvitge, (L’Hospitalet
de Llobregat, Spain), Complejo Asistencial Universitario (León, Spain), and Hospital Uni-
versitari Arnau de Vilanova (Lleida, Spain). SCCC patients’ demographic, pathological,
and clinical characteristics are summarized in Table S6. No clinical follow-up was available
for HSIL or BL patients, since they were all successfully cured by surgery. All tumors
were surgically removed and staged according to their size, histological grade, and lymph
node involvement. All cases were ensured to harbor at least 70% tumor cells, and none
of the patients had received radiotherapy or chemotherapy before surgery. The study
was approved by the Navarre Ethics Committee for Clinical Research (PI_2018/75) on
30 September, 2019, procedures were in accordance with the Declaration of Helsinki of
1975 and revised in 2013, and biopsies were obtained in accordance with current Spanish
legislation regarding informed consent. All samples were double-coded by clinicians and
researchers to ensure anonymity.
4.2. Cell Lines
Three human CC cell lines were used in this study: two SCCC-derived cell lines
(C-33A and SiHa, HPV-negative and HPV16-positive SCCCs, respectively), and a cell line
derived from an HPV18-positive cervical adenocarcinoma (HeLa). Additionally, 293T
cells were used for dual-luciferase reporter assays. All cell lines were purchased from
the American Type Cell Collection (Rockville, MD, USA). They were all grown in DMEM
supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin (all from
Thermo Fisher Scientific, Waltham, MA, USA), at 37 ◦C in a humidified atmosphere with
5% CO2. Experiments were performed with Mycoplasma-free and recently authenticated
cell lines at low passage.
4.3. RNA Extraction and Quantitative Reverse-Transcription Polymerase Chain Reaction (qRT-PCR)
To determine miR-877-3p and ZNF177 mRNA levels in cervical samples, the RNA
fraction was first isolated from our series of FFPE samples and CC cell lines using the
RecoverAllTM total nucleic acid isolation kit (Thermo Fisher Scientific, Waltham, MA, USA)
following the manufacturer’s instructions. Briefly, 15-µm sections were deparaffinized
with xylene and dried with 100% ethanol in a vacuum for 30 min at room temperature.
Samples were protease-digested for 15 min at 50 ◦C followed by 15 min at 80 ◦C. RNA was
precipitated with an isolation additive and ethanol mixture, washed, DNase-treated for
30 min at room temperature, and washed again using filter columns in the kit. Finally, RNA
was eluted from the column with 30 µL of RNase-free water, and concentration and quality
were assessed using a NanoDrop spectrophotometer (Thermo Fisher Scientific, Waltham,
MA, USA).
Next, qRT-PCR was performed as follows. For miR-877-3p expression, 100 ng of total
RNA per each miRNA to be analyzed were retrotranscribed using the TaqMan® microRNA
reverse transcription kit and specific TaqMan® primers for each miRNA (hsa-miR-877-
3p: 241029_mat; and endogenous RNU48: 001006) at 16 ◦C for 30 min, 42 ◦C for 30 min
and 85 ◦C for 5 min. One µL of the resulting cDNA was mixed with the TaqMan®, No
AmpErase® UNG universal PCR master mix and specific TaqMan® probes for each miRNA
(all reagents from Thermo Fisher Scientific, Waltham, MA, USA). For ZNF177 mRNA
expression, 200 ng of total RNA were retrotranscribed using the PrimeScriptTM RT reagent
kit (TaKaRa, Otsu, Japan) at 37 ◦C for 15 min and 85 ◦C for 5 s. One µL of cDNA was mixed
with specific TaqMan® probes (ZNF177: Hs.PT.58.25734794; and the endogenous GAPDH:
Hs.PT.39a.22214836, both from Integrated DNA Technologies, Coralville, IA, USA), and the
buffer included in the Premix Ex TaqTM kit (TaKaRa, Otsu, Japan). All PCR amplifications
were performed in triplicate using the Quant Studio 12K Flex (Thermo Fisher Scientific,
Waltham, MA, USA) under thermal cycler conditions of: (i) 95 ◦C for 10 min and 40 cycles
at 95 ◦C for 15 s and 60 ◦C for 1 min, to amplify miRNAs; and (ii) 95 ◦C for 30 s and
40 cycles at 95 ◦C for 5 s and 60 ◦C for 34 s, for mRNAs. The cycle threshold (Ct) values
were calculated using Quant Studio software (Thermo Fisher Scientific, Waltham, MA,
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USA), and the relative quantification (RQ) was calculated by the ∆Ct method (RQ = 2−∆Ct),
using RNU48 or GAPDH as the endogenous miRNA or gene control, respectively.
4.4. miR-877-3p Silencing in CC Cell Lines
To study the functional role of miR-877-3p in CC, C-33A, SiHa and HeLa cell lines
were transfected with an anti-miR-877-3p (Cat# AM17000, ID AM13557) and a Cy3-labelled
anti-miR scramble as a negative control (NC) (Cat# AM17011), which did not target any
known human miRNA (both from Thermo Fisher Scientific, Waltham, MA, USA), at several
concentrations and times. Briefly, 1 × 105 cells/well were plated in six-well plates and
allowed to attach overnight. Next day, anti-miRs were diluted in 200 µL of DMEM with
2 µL of the INTERFERin® transfection agent (Polyplus-transfection SA, Illkirch, France),
incubated for 10 min at room temperature and added to the cells. Transfection efficiency
was checked by flow cytometry: at each time, non-transfected (MOCK) and NC-transfected
cells were harvested, washed twice with phosphate-buffered saline (PBS), and resuspended
in 200 µL of PBS. The percentage of Cy3-positive cells was then determined by acquiring
10,000 cells in a FACS Canto flow cytometer (Beckton Dickinson, BD, Franklin Lakes,
NJ, USA) with the FACS DIVA (BD, Franklin Lakes, NJ, USA) and the FlowJo programs
(LLC, Ashland, OR, USA). Furthermore, miR-877-3p levels were measured by qRT-PCR, as
described above, in MOCK, NC-transfected and anti-miR-877-3p-transfected cells to check
knockdown efficiency.
4.5. Effects of miR-877-3p Inhibition on CC Cell Survival
To test the functional consequences of miR-877-3p knockdown on CC cell survival,
C-33A, SiHa and HeLa cell lines were transfected with NC and anti-miR-877-3p for 4 days,
and several vital characteristics were measured. First, cell proliferation was interrogated
by fixing and staining cells with a paraformaldehyde-containing crystal violet solution
(Sigma-Aldrich, St Louis, MO, USA). Images were acquired with a Leica DM4000B mi-
croscope (Leica, Wetzlar, Germany) and the NIS Elements program (Nikon Instruments,
Amsterdam, Netherlands) at 50× magnification. Absorbance at 590 nm was measured
with an Epoch plate reader (BioTek, Winooski, VT, USA). Second, apoptosis induction was
examined by flow cytometry using the APC-Annexin V binding assay. Briefly, MOCK,
NC-transfected and anti-miR-877-3p-transfected cells were harvested, washed twice with
PBS, and resuspended in 200 µL of Annexin V-binding buffer with 2 µL APC-Annexin
V (BioLegend Way, San Diego, CA, USA) and 0.5 µL of DAPI. Data were recorded on a
FACS Canto flow cytometer, as described above. Finally, cell distributions during each
cell cycle phase were also evaluated by flow cytometry. Similarly, MOCK, NC-transfected
and anti-miR-877-3p-transfected cells were harvested, washed twice with PBS, fixed with
ice-cold 70% ethanol for at least 1 h at 4 ◦C, and resuspended in 200 µL of PBS with 10 µL
of propidium iodide and 1 µL of RNase A for 30 min at room temperature in darkness, and
analyzed using a FACS Canto flow cytometer, as described above.
4.6. Cell Migration
In order to test the effects of miR-877-3p knockdown on CC cell migration, C-33A,
SiHa, and HeLa cells were seeded and transfected with NC and anti-miR-877-3p until
confluence was almost reached. Cells were then FBS-starved for 8 h, and three scratches
were made on the cell monolayer with a 10-µL pipette tip. Some cells were fixed and
stained with crystal violet, while others were maintained for two more days in a 5% FBS
containing medium, and then fixed and stained. Finally, 10 pictures were taken with
a Leica DM4000B microscope (Leica, Wetzlar, Germany) at 50× magnification, and the
scratch width was measured to calculate the migration index as the scratch width at 0 days
minus that at 2 days, with the NIS Elements program (Nikon Instruments, Amsterdam,
Netherlands), from more than 10 measurements taken from each picture, as previously
described [110].
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4.7. Cell Invasion
The effects of miR-877-3p silencing on CC cell invasion were also determined. To do
this, C-33A, SiHa and HeLa cells were transfected with NC and anti-miR-877-3p, as de-
scribed above, for 4 days. Cells were FBS-starved overnight, trypsinized and 1.25× 105 cells
were re-seeded in FBS-free DMEM on a 40-µL Matrigel® layer (BD, Franklin Lakes, NJ,
USA), which had been previously allowed to gel for 15–30 min at 37 ◦C in Transwell®
inserts with an 8-µm-pore membrane (Sarstedt, Nümbrecht, Germany). Inserts were placed
in wells with 10% FBS-containing medium, and maintained for three more days. Finally,
the gel layer was removed with a cotton-tipped swab, and invading cells that had reached
the membrane were fixed and stained with a paraformaldehyde-containing crystal violet
solution. Images were captured under a Leica DMi1 microscope with the Leica Application
Suite v4.12 program (Leica, Wetzlar, Germany) at 50×magnification. The area occupied
by invading cells was measured with the NIS Elements program (Nikon Instruments,
Amsterdam, Netherlands).
4.8. Dual-Luciferase Reporter Assay
A dual-luciferase reporter assay was carried out to test whether the expression of
the in silico predicted target ZNF177 was actually regulated by the miR-877-3p. To this
end, the wild type (wt) 3′UTR region of the ZNF177 gene was obtained from Thermo
Fisher Scientific (Waltham, MA, USA). Similarly, a mutated (mut) 3′UTR region was
also purchased, in which six nucleotides strategically located in the putative miR-877-
3p-binding site were modified from the wt sequence in order to weaken the potential
binding. The wt and mut 3′UTR regions were both cloned into the pGL3-control luciferase
reporter vector, which contained the firefly luciferase gene without the 3′UTR region
(kindly provided by Dr. Rubén Hernández-Alcoceba, Gene Therapy Program, Center for
Applied Medical Research, Pamplona, Spain). To achieve this, plasmids were digested with
the XbaI restriction enzyme and ends from the pGL3-control vector were dephosphorylated
with FastAP thermosensitive alkaline phosphatase for 40 min at 37 ◦C and for 20 min at
80 ◦C to inactivate the enzyme. Digested plasmid and inserts were incubated with 1 µL of
the T4 ligase for 20 min at room temperature. TOP10 Chemically Competent Escherichia coli
bacteria were heat-shock-transformed with 4 µL of the ligation reaction (all reagents from
Thermo Fisher Scientific, Waltham, MA, USA). Cloning was confirmed by XbaI-digestion
and sequencing using the 5′-CGTCGCCAGTCAAGTAACAA-3′ primer. Finally, 293T cells
were cotransfected with the cloned firefly luciferase + ZNF177-3′UTR insert, the Renilla
luciferase reporter plasmid (also kindly provided by Dr. Rubén Hernández-Alcoceba, Gene
Therapy Program, Center for Applied Medical Research, Pamplona, Spain), and the NC
or the anti-miR-877-3p, as explained above. After 48 h, firefly and Renilla luminescence
were measured using the DUAL-Glo® luciferase assay system kit (Promega, Madison, WI,
USA) in an Epoch plate reader (BioTek, Winooski, VT, USA), following the manufacturer’s
instructions, and the ratio of firefly to Renilla luciferase expression was calculated.
4.9. ZNF177 Overexpression
The coding region of the ZNF177 gene (Thermo Scientific, Waltham, MA, USA)
was cloned into the pcDNA3.1 plasmid (Addgene, Watertown, MA, USA) using BamHI
and NotI restriction enzymes (Thermo Scientific, Waltham, MA, USA) and E. coli XL-1
blue bacteria. Insert ligation was checked by digestion with BamHI and NotI restric-
tion enzymes, and by sequencing. Due to the large size of the amplicon (1967 bp),
two sequencing primers were used: 5′-TGTGATGCTGGAGAACTTTAGG-3′, and 5′-
GGCCGCCTATTTGTCATCATC-3′. After checking ligation, SCCC cell lines were trans-
fected with the empty vector and the vector + ZNF177 construct using FuGene6 (Promega,
Madison, WI, USA). Transfected C-33A and SiHa cells were selected with 500 µM and
1000 µM of G418 (Invivogen, Toulouse, France), respectively, for 13 days. Transfection
efficiency was then checked by measuring ZNF177 mRNA levels by qRT-PCR, as described
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above. Effects of ZNF177 overexpression on SCCC cell proliferation and migration were
evaluated at 72 h and 48 h, respectively, as explained above.
4.10. Subcellular Fractionation
Cells were lysed with a PBS-based buffer containing 1% NP-40 (Thermo Scientific,
Waltham, MA, USA) and protease inhibitors (Roche, Basel, Switzerland), scraped, and
centrifuged at 13,000 rpm for 1 min at 4 ◦C. Cytoplasmic proteins in the supernatant were
collected and precipitated with ice-cold acetone, while pellets were resuspended in 50 µL
of lysis buffer (7M urea, 2M thiourea, and 50 mM DTT), incubated on ice for 30 min and
sonicated for two cycles of 20 s each. Finally, samples were centrifuged at 20,000× g
for 20 min at 15 ◦C, and nuclear proteins were collected from the supernatant. Protein
concentration was measured in the supernatants with the Bradford assay kit (Bio-Rad,
Hercules, CA, USA). Detection of GAPDH protein preferentially in the cytosolic fraction,
in addition to major histone H3 location in the nuclear fraction, indicated the efficiency of
the enrichment procedure (Figure S11).
4.11. Label-Free Liquid Chromatography–Tandem Mass Spectrometry (LC–MS/MS)
The discovery phase (shotgun proteomics) was performed in two subcellular fractions
(nucleus and cytoplasm) from two SCCC cell lines (C-33A and SiHa) with three biological
replicates for each experimental condition: MOCK, NC-transfected and anti-miR-877-3p-
transfected cells (36 samples in total). The size of the groups meant that the biological
variation could be evened out. Protein extracts for each sample were diluted in Laemmli
sample buffer and loaded into a 0.75-mm-thick polyacrylamide gel with a 4% stacking
gel cast on a 12.5% resolving gel. The run was stopped as soon as the front had pene-
trated 3 mm into the resolving gel so that the whole proteome became concentrated in the
stacking/resolving gel interface. Bands were stained with Coomassie Brilliant Blue and
excised from the gel. Protein enzymatic cleavage (20 µg) was carried out with trypsin (1:20,
w/w) (Promega, Madison, WI, USA) at 37 ◦C for 16 h, as previously described [111]. Pep-
tides were purified and concentrated using C18 Zip Tip Solid Phase Extraction (Millipore,
Burlington, MA, USA). Peptide mixtures were separated by reverse-phase chromatogra-
phy using an Eksigent nanoLC ultra 2D pump fitted with a 75-µm ID column (Eksigent
0.075× 250). Samples were first loaded for desalting and concentration into a 0.5-cm length
100-µm ID precolumn, packed with the same chemicals as the separating column. Mobile
phases were 100% water with 0.1% formic acid (FA) (buffer A), and 100% acetonitrile with
0.1% FA (buffer B). The column gradient was developed in a 240-min two-step gradient
from 5% B to 25% B in 210 min and 25% B to 40% B in 30 min. The column was equilibrated
in 95% B for 9 min and 5% B for 14 min. Throughout the process, the precolumn was
in line with the column and the flow was maintained along the gradient at 300 nl/min.
Eluting peptides from the column were analyzed with a Sciex 5600 Triple-TOF system
(Sciex, Framingham, MA, USA). Data were acquired from a survey scan performed on
a mass ranging from 350 to 1250 m/z in a scan time of 250 ms. The top 35 peaks were
selected for fragmentation. The minimum accumulation time for MS/MS was set to 100 ms,
giving a total cycle time of 3.8 s. Product ions were scanned in a mass range from 230 to
1500 m/z and were excluded from further fragmentation for 15 s.
4.12. Peptide Identification and Quantification
MS/MS data were acquired using Analyst 1.7.1 (Sciex, Framingham, MA, USA).
Spectra files were processed with Protein Pilot software v.5.0 (Sciex, Framingham, MA,
USA) using the Paragon™ algorithm (v.4.0.0.0) for database searching [112], Progroup™
for data grouping, and searched against the concatenated target-decoy UniProt proteome
reference human database (Proteome ID: UP000005640, 73,045 proteins, April 2018) plus
human papillomavirus type 16 database (Taxon identifier: 333760, nine reviewed proteins,
April 2018). Both databases were compiled using Notepad++ software. The data were
searched with respect to the fixed modification of carbamidomethyl (C) and the following
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variable modifications: oxidation (M), deamidation (NQ), glutamine to pyro-glutamate (N-
terminus), with a one-missed tryptic cleavage threshold and a 10-ppm mass error tolerance
for precursor and 20 ppm for fragment ions. Only spectra with 95% confidence or better
were considered. The false-discovery rate (FDR) was estimated by a non-linear fitting
method [113] and the results displayed were those reporting a 1% global FDR or better.
The peptide was quantified with Progenesis LC−MS software (v.2.0.5556.29015, Nonlinear
Dynamics). Runs were aligned to compensate for between-run variations in our nanoLC
separation system using the accurate mass measurements from full survey scans in the
TOF detector and the observed retention times. All runs were aligned to a reference run
that was automatically chosen by the software, and a master list of features considering
m/z values and retention times was generated. The quality of these alignments was
manually supervised with the help of quality scores provided by the software. The peptide
identifications were exported from Protein Pilot software and imported into the Progenesis
LC−MS program, where they were matched to the respective features. Output data files
were managed with Perseus software [114] to enable statistical analyses and representation.
Proteins identified by site (identification based only on a modification), reverse proteins
(identified by decoy database) and potential contaminants were filtered out. Principal
component analysis was performed on the normalized and filtered datasets. After checking
the data were normally distributed, significantly different protein levels were calculated by
ANOVA with a permutation-based FDR cut-off (250 randomizations, FDR < 0.05). Proteins
quantified with at least two unique peptides, an ANOVA significance of p < 0.05, and an
absolute < 0.77-fold (downregulation) or > 1.3-fold (upregulation) change in linear scale
were considered to be significantly differentially expressed. MS raw data and search results
files have been deposited to the ProteomeXchange Consortium (http://proteomecentral.
proteomexchange.org accessed on 8 February 2019) via the Proteomics Identifications
Database (PRIDE) partner repository [115], with the dataset identifier PXD014993.
4.13. Bioinformatic Analysis
The disrupted biological functions triggered by miR-877-3p inhibition were inter-
rogated using several bioinformatic tools: DAVID v6.8 (https://david.ncifcrf.gov/ ac-
cessed on 5 November 2018) [116], PANTHER v.14.1 (http://pantherdb.org/ accessed on
5 November 2018) [117] and UniProtKB/Swiss-Prot (https://www.uniprot.org/ accessed
on 5 November 2018) databases. Data from each cell line were integrated using the STRING
v11.0 tool (https://string-db.org/ accessed on 23 January 2019) [118]. The Ingenuity Path-
way Analysis (IPA) program (release date: 2019-02-08, https://www.qiagenbioinformatics.
com/products/ingenuity-pathway-analysis accessed on 2 May 2019) (Qiagen, Hilden,
Germany) [119] was also used to generate larger networks by adding other functionally
related and published proteins that were not detected here. Finally, the Metascape tool
(http://metascape.org/) [120] ( accessed on 23 May 2019) was used to integrate functional
data from the two cell lines.
4.14. Western Blot
To check subcellular fractionation efficiency, cytoplasmic and nuclear proteins were
separately extracted from MOCK, NC-transfected and anti-miR-877-3p-transfected C-
33A and SiHa cells, as explained above, and subjected to western blot. To confirm that
miR-877-3p regulated the expression of some potential targets, p16, ZNF177, GPC1, and
CCT3 protein levels were determined by western blot in miR-877-3p-silenced SCCC cell
lines. Whole-cell protein extracts were isolated from NC-transfected and anti-miR-877-3p-
transfected C-33A and SiHa cells by lysing with 30 µL of radioimmunoprecipitation assay
(RIPA) buffer (Sigma-Aldrich, St Louis, MO, USA) and a cocktail of protease inhibitors
(Roche, Basel, Switzerland). Proteins were collected from supernatants after centrifuging at
8000× g for 10 min at 4 ◦C. For western blot, 60 µg of protein were resolved by SDS-PAGE in
a Criterion™ TGX Stain-Free™ protein gel, and transferred onto a nitrocellulose membrane
(both from Bio-Rad, Hercules, CA, USA), which was blocked with 5% non-fat milk. Mem-
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branes were incubated with anti-p16 (805–4713, Roche, Basel, Switzerland), anti-ZNF177
(ab50718, Abcam, Cambridge, UK), anti-GPC1, and anti-CCT3 (CSB-PA009703LA01HU and
A6547, from Antibodyplus, Inc., Brookline, MA, USA) antibodies at 250 ng/mL, 1:100, 1:500,
and 1:500, respectively, overnight and at 4 ◦C. They were then incubated with secondary
anti-rabbit or anti-mouse antibodies (Bio-Rad, Hercules, CA, USA) at 1:2000 for 1 h at room
temperature. The signal was detected with the SuperSignal West Pico Chemiluminescent
Substrate kit (Thermo Scientific, Rockford, IL, USA) in a ChemiDoc imaging system (Bio-
Rad, Hercules, CA, USA) using ImageLab software. The GAPDH (CB1001, Calbiochem,
Burlington, MA, USA), histone H3 (ab17684, Abcam, Cambridge, UK), and α-tubulin
(T-6074 from Sigma-Aldrich, St Louis, MO, USA) antibodies were employed as loading
controls for cytoplasmic, nuclear and whole-cell protein fractions, respectively. Finally, the
intensity of bands was quantified by densitometric analysis using the ImageJ program. All
whole blots showing all the bands, molecular markers and complete quantifications are
shown in the Figure S12.
4.15. Immunohistochemistry
Four-µm sections of FFPE cervical lesions were placed on slides and deparaffinized,
hydrated and treated to block endogenous peroxidase activity. After incubating with anti-
ZNF177 antibody (HPA003141, Sigma-Aldrich, St Louis, MO, USA) at 1:60 for 1 h (antigen
retrieval at 90 ◦C for 30 min, pH 6.0), the signal was developed using a Bond Polymer
Refine Detection kit (Leica, Wetzlar, Germany) and visualized with diaminobenzidine.
Sections of an FFPE testis were also included as a positive control of ZNF177 staining, as
recommended by the antibody manufacturers. The pattern and intensity of expression were
evaluated blind by two independent observers (T.Z. and E.M.-S.), and cases were ascribed
to one of four categories: 0, no expression; 1, weak expression; 2, moderate expression; 3,
strong expression (Figure S13). Finally, an immunohistochemical score was defined for
each sample as the mean of the observers’ evaluation. Images were acquired with a Leica
DM4000B microscope (Leica, Wetzlar, Germany) and the NIS Elements program (Nikon
Instruments, Amsterdam, The Netherlands) at 200× and 400×magnifications.
4.16. Response to Paclitaxel
To determine whether miR-877-3p was involved in response to paclitaxel, CC cell
sensitivity to paclitaxel was first evaluated. To do this, C-33A, SiHa and HeLa cells were
seeded in 96-well plates at a density of 1 × 104 cells/well, allowed to attach overnight, and
treated with a wide range of paclitaxel (Selleck Chemicals, Houston, TX, USA) doses for
72 h, using DMSO (Sigma-Aldrich, St Louis, MO, USA) as vehicle control. Cell viability
was measured as the intracellular ATP content using the CellTiter-Glo® luminescent cell
viability assay (Promega, Madison, WI, USA), and IC50 values were calculated as previously
described [121]. Next, miR-877-3p silencing and paclitaxel treatment were carried out
simultaneously, and cell morphology, viability, and migration were monitored under a
Leica DMi1 microscope for 24, 48, and 72 h, as described above. Images were taken at each
time with the Leica Application Suite v4.12 program (Leica, Wetzlar, Germany) at 50×
and 200×magnifications. The nature of the combination was mathematically determined
using the Bliss independence principle [122,123], which enabled the calculation of the
predicted inhibitory effect of the double targeting based on the inhibitory effect observed
after individual administration, under the assumption that drugs acted independent of
each other, as:
PEcombination = OEanti-miR-877-3p + OEpaclitaxel − OEanti-miR-877-3p × OEpaclitaxel
where PEcombination is the predicted effect of the combination; OEanti-miR-877-3p is the ob-
served effect of the anti-miR-877-3p; and OEpaclitaxel is the observed effect of paclitaxel.
If the observed inhibitory effect of the drug combination (OEcombination) is equal the
PEcombination, drugs act independently; if the OEcombination is greater than the PEcombination,
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the combination is considered as synergistic; and if the OEcombination is lower than the
PEcombination, the combination is antagonistic.
4.17. Statistical Analysis
Patients’ demographic, clinical, pathological, and molecular data were summarized
as frequencies (and percentages) and means (and ranges) ± standard error of the mean, as
appropriate. Unless otherwise specified, all in vitro experiments were carried out in three
biological replicates from three CC cell lines. All statistical analyses, except those involving
bioinformatics (detailed above), were carried out using IBM SPSS Statistics v25. Group
differences of each variable were compared by Student’s independent samples t-test or the
Mann–Whitney test, as appropriate. Associations among variables were estimated by χ2
or Fisher’s exact tests. Kaplan–Meier plots and log-rank tests were used to examine the
association of molecular biomarker expression and subcellular location with progression-
free survival and overall survival. A multivariate Cox regression model was fitted to
test the independent contribution of each variable to patient’s outcome after adjustment.
Hazard ratios and 95% confidence intervals were used to estimate the effect of each variable
on the outcome. Sensitivity and specificity of ZNF177 subcellular location in predicting
prognosis and diagnosis was calculated by performing receiver operating curve analysis.
5. Conclusions
In conclusion, our findings as a whole suggest tools that could improve the clinical
management of CC, based on an understanding of the miR-877-3p molecular mechanism.
First, miR-877-3p inhibition could be a therapeutic strategy that impairs CC cell migration
and invasion through cytoskeletal protein remodeling and cooperation with paclitaxel.
Second, the expression of one of its targets, ZNF177, could be a potential diagnostic
biomarker distinguishing HSIL from SCCC. Finally, cytoplasmic ZNF177 levels potentially
predict poor prognosis in SCCC patients.
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